Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 8OTHER 2NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1CNS 1

Conditions

Recurrence 1Neoplasms 1Multiple Myeloma 1Diffuse Intrinsic Pontine Glioma 1

Interventions

Cyclophosphamide 2067Radiotherapy 1990Cisplatin 1856Carboplatin 1560Gemcitabine 1454Paclitaxel 1320Bevacizumab 1320pembrolizumab 1238Docetaxel 1227Oxaliplatin 1184Capecitabine 1178Fluorouracil 1083Dexamethasone 979Magnetic Resonance Spectroscopy 971Nivolumab 936Rituximab 929Drug Therapy 915Surveys and Questionnaires 899Doxorubicin 845Etoposide 843Radiosurgery 816Blood Specimen Collection 816Irinotecan 784Cytarabine 743fludarabine 726Leucovorin 684Surgical Procedures, Operative 640Lenalidomide 618Biopsy 594fludarabine phosphate 569

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × marizomib × Clear all
NCT05050305 2024-07-16

Marizomib Central Nervous System (CNS)

Dana-Farber Cancer Institute

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma

NCT04341311 2024-02-15

DIPG

Dana-Farber Cancer Institute

Phase 1 Terminated
4 enrolled
CNS

Diffuse Intrinsic Pontine Glioma, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡